Canada · Delayed Price · Currency is CAD InnoCan Pharma Company Description
InnoCan Pharma Corporation, a pharmaceutical technology company, focuses on the development of various drug delivery platforms combining cannabidiol (CBD) with other pharmaceutical ingredients in the United States, Canada, Europe, and internationally.
The company operates in two segments: Online Sales and Other Operations. It engages in the research and development of CBD loaded exosomes, as well as operates LPT CBD-loaded liposome platform that facilitates exact dosing and the prolonged and controlled release of CBD into the blood stream for epilepsy and pain management.
The company is involved in the development and sale of CBD-integrated pharmaceuticals and topical products.
In addition, it develops and markets a portfolio of self-care products for healthier lifestyle. The company was incorporated in 2018 and is headquartered in Calgary, Canada.
| Country | Canada |
| Founded | 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| CEO | Iris Bincovich |
Contact Details
Address: 1015, 926 – 5 Avenue SW Calgary, T2P 0N7 Canada | |
| Phone | 403-777-1519 |
| Website | innocanpharma.com |
Stock Details
| Ticker Symbol | INNO |
| Exchange | Canadian Securities Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | CA45783P1027 |
| SIC Code | 2833 |
Key Executives
| Name | Position |
|---|---|
| Iris Bincovich | Chief Executive Officer and Interim Chair |
| Nelson Harvey Halpern F.C.A., FCPA | Chief Financial Officer |
| Roni Kamhi | Chief Operating Officer and Director |
| Eyal Flom L.L.M., M.B.A. | Company Secretary, General Counsel and Director |